150.24
-3.09%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Asymchem Laboratories (Tianjin) Co
Its shares trade on Shenzhen under the ticker 002821.SZ. It has been listed since 18 November 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥6.67bn and net income of CN¥1.13bn. At that date it held total assets of CN¥20.28bn and shareholders' equity of CN¥17.64bn.
Asymchem Laboratories Tianjin Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2016-11-18. Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The firm's main businesses are the process development, amplification and commercialization of chemical drugs. The firm's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The firm is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Nov 2016
- Employees
- 9,719
- Website
- asymchem.com.cn ↗
Leadership
Pay as last reported
- Mr. Hao HongExecutive Chairman of the Board, Chief Executive Officer, since 2011CN¥5.5m
- Ms. Rui YangCo-Chief Executive Officer, Executive Director, since 2011CN¥5.3m
- Mr. Da ZhangChief Financial Officer, Chief Operating Officer, Executive Director, since 2018CN¥3.8m
- Mr. Liang HongExecutive Vice President, Staff Elected Director, since 2011CN¥2.5m
- Mr. Chaoyong ChenExecutive Vice PresidentCN¥3.1m
- Mr. Yingwei JiangExecutive Vice PresidentCN¥3.1m
- Mr. Xiangke XuSenior Vice President, Secretary of the BoardCN¥1.6m
- Mr. Yan ZhouSenior Vice PresidentCN¥1.7m
- Mr. Chengyi ChenChief Technology Officer
- Mr. Xinhui HuChief Business OfficerCN¥5.1m
- Ms. Ye SongNon-Executive DirectorCN¥713,300
- Ms. Ting ZhangNon-Executive DirectorCN¥1.6m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 99
- Social
- 85
- Governance
- 81
- Direct emissions (scope 1)
- 31,786.56 t
- Energy emissions (scope 2)
- 204,882.44 t
- Women in the workforce
- 32.26%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Asymchem Laboratories employs 9,719 full-time employees in Tianjin, China.
- The company specializes in CDMO services for peptides, oligonucleotides, and monoclonal antibodies.
- Asymchem offers pharmaceutical formulation and biosynthetic solutions for drug development.
Weaknesses
- The company's IPO was on 18 November 2016, which may limit recent growth opportunities.
- Asymchem operates solely in Tianjin, China, with no international presence mentioned.
- The firm's focus on CDMO services might restrict diversification into other pharmaceutical segments.
Opportunities
- The growing demand for mRNA drugs presents a significant opportunity for Asymchem's product portfolio.
- China's expanding pharmaceutical market offers potential for increased contract manufacturing contracts.
- Asymchem can leverage its expertise in oligonucleotides to enter new therapeutic areas.
Threats
- The pharmaceutical industry faces increasing regulatory scrutiny in China and globally.
- Competition from other CDMOs in China could impact market share.
- Rising raw material costs may affect profitability in the pharmaceutical manufacturing sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.